Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma Sells 2,000 Shares

Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) President Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $10.85, for a total transaction of $21,700.00. Following the transaction, the president now directly owns 2,911,138 shares of the company's stock, valued at $31,585,847.30. The trade was a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Songjiang Ma also recently made the following trade(s):

• On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.10, for a total transaction of $565.60.
• On Friday, January 10th, Songjiang Ma sold 1,057 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.02, for a total transaction of $10,591.14.
• On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.16, for a total transaction of $9,560.56.
• On Thursday, January 2nd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.40, for a total value of $24,800.00.
• On Monday, December 30th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.50, for a total transaction of $25,000.00.
• On Thursday, December 26th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.70, for a total value of $25,400.00.
• On Monday, December 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.27, for a total value of $24,540.00.
• On Thursday, December 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.82, for a total transaction of $21,640.00.
• On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.05, for a total transaction of $22,100.00.

Gyre Therapeutics Stock Performance

GYRE stock traded down $0.13 during trading on Thursday, hitting $10.80. 78,155 shares of the company's stock traded hands, compared to its average volume of 141,994. The business has a fifty day simple moving average of $11.74 and a two-hundred day simple moving average of $12.65. Gyre Therapeutics, Inc. has a 1 year low of $8.26 and a 1 year high of $26.37.

Institutional Investors Weigh In On Gyre Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. boosted its position in shares of Gyre Therapeutics by 392.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company's stock worth $1,425,000 after purchasing an additional 90,557 shares in the last quarter. Geode Capital Management LLC lifted its position in Gyre Therapeutics by 16.9% during the 3rd quarter. Geode Capital Management LLC now owns 303,647 shares of the company's stock worth $3,808,000 after acquiring an additional 43,840 shares during the period. Advantage Alpha Capital Partners LP purchased a new stake in Gyre Therapeutics during the 3rd quarter valued at about $334,000. WINTON GROUP Ltd acquired a new position in shares of Gyre Therapeutics in the second quarter valued at about $220,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Gyre Therapeutics in the second quarter worth about $218,000. 23.99% of the stock is currently owned by hedge funds and other institutional investors.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.